Entresto Generics Loom In India But Wait, Novartis Just Got A Patent
Executive Summary
There’s been a significant twist in the Entresto case in India with Novartis securing a patent, but can that put off the launch of generic versions of the blockbuster heart failure therapy later this month?
You may also be interested in...
Five Big Pharma Products That Saw Action In India; There’s More To Come
Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.
Entresto Patent Order Quashed In India, Market Ripe For Action
Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.
Entresto Patent Order Quashed In India, Market Ripe For Action
Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.